PTO/SB/05 (08-03) Q
Approved for use through 07/31/2006. OMB 0651-0032 O
U.S. Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control num

UTILITY PATENT APPLICATION **TRANSMITTAL**

(Only for new nonprovisional applications under 37 CER 1 53/h))

	and alloca it displays a valia sing control falliper.	
Attorney Docket No.	02-175	
First Inventor	Elzein	
Title	Substituted Heterocyclic Compounds	
Express Mail Label No.	EJ 765 893 765 US	

(Only for ne	ew nonprovisional applications under 37 CPR 1.33(b))	Express Mail Label No. E3 703 693 703 03	
See MPEP ch	APPLICATION ELEMENTS hapter 600 concerning utility patent application contents.	ADDRESS TO: Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450	
2. Applicat See 37 3. Specific (preferre - Descrip - Cross F - Statem - Referee or a coo - Backgr - Brief S - Brief D	ord arrangement set forth below) ptive title of the invention Reference to Related Applications nent Regarding Fed sponsored R & D ence to sequence listing, a table, computer program listing appendix round of the Invention summary of the Invention bescription of the Drawings (if filed) and Description	7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. Computer Readable Form (CRF) b. Specification Sequence Listing on: i. CD-ROM or CD-R (2 copies); or ii. Paper c. Statements verifying identity of above copies ACCOMPANYING APPLICATION PARTS	
4. Drawing 5. Oath or Decla a. New b. Copy (for c) i. <u>C</u> s n 1 6. Applie	yly executed (original or copy) y from a prior application (37 CFR 1.63(d)) continuation/divisional with Box 18 completed) DELETION OF INVENTOR(S) igned statement attached deleting inventor(s) name in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b). cation Data Sheet. See 37 CFR 1.76	9. Assignment Papers (cover sheet & document(s)) 10. 37 CFR 3.73(b) Statement Power of (when there is an assignee) Attorney 11. English Translation Document (if applicable) 12. Information Disclosure Copies of IDS Statement (IDS)/PTO-1449 Citations 13. Preliminary Amendment 14. Return Receipt Postcard (MPEP 503) (Should be specifically itemized) 15. Certified Copy of Priority Document(s) (if foreign priority is claimed) 16. Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent. 17. Other:	
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in the first sentence of the specification following the title, or in an Application Data Sheet under 37 CFR 1.76: Continuation Divisional Continuation-in-part (CIP) of prior application No.: Art Unit: For CONTINUATION OF DIVISIONAL APPS only; The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.			
19. CORRESPONDENCE ADDRESS			
Custome	er Number: 27716	OR Correspondence address below	
Name CV Therapeutics, Inc.			
Address 3172 Porter Drive			
	Palo Alto	State California Zip Code 94304	
Country United States Telephone (650) 384-8500 Fax (650) 858-038		Telephone (650) 384-8500 Fax (650) 858-0390	
Name (Print/Type) Brian Lewis Registration No. (Attorney/Agent) 32,502			
Signature	Brian Lewin	Date December 5, 2003	

This collection of information is required by 37 CFR 1.53(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/17 (10-03) Approved for use through 07/31/2006. OMB 0651-0032 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. C mplete if Known FEE TRANSMITTAL **Application Number** for FY 2004 Filing Date Elzein First Named Inventor Effective 10/01/2003. Patent fees are subject to annual revision. **Examiner Name** Applicant claims small entity status. See 37 CFR 1.27 Art Unit (\$) 394.00 **TOTAL AMOUNT OF PAYMENT** 02-175 Attorney Docket No METHOD OF PAYMENT (check all that apply) FEE CALCULATION (continued) Money Order Check Credit card Other None 3. ADDITIONAL FEES arge Entity | Small Entity Deposit Account: Fee **Fee Description** Deposit Code (\$) Code Fee Paid 50-1789 Account 1051 130 2051 65 Surcharge - late filing fee or oath Number Deposit 1052 50 2052 25 Surcharge - late provisional filing fee or CV Therapeutics, Inc. Account cover sheet Name 1053 130 1053 130 Non-English specification The Director is authorized to: (check all that apply) 1812 2,520 1812 2,520 For filing a request for ex parte reexamination Charge fee(s) indicated below Credit any overpayments 920* Requesting publication of SIR prior to 1804 9201 1804 ✓ Charge any additional fee(s) or any underpayment of fee(s) Examiner action Charge fee(s) indicated below, except for the filing fee 1805 1,840* Requesting publication of SIR after 1805 1.840 Examiner action to the above-identified deposit account. 2251 1251 110 55 Extension for reply within first month **FEE CALCULATION** 210 Extension for reply within second month 1252 420 2252 1. BASIC FILING FEE 1253 950 2253 475 Extension for reply within third month arge Entity Small Entity Fee Description Fee Paid F<u>ee</u> Fee Fee Code (\$) 1254 1,480 2254 740 Extension for reply within fourth month Code (\$) 1,005 Extension for reply within fifth month 1255 2,010 2255 1001 770 2001 385 Utility filing fee 385.00 2002 170 Design filing fee 1401 330 2401 165 Notice of Appeal 1002 340 1003 2003 1402 330 2402 165 Filing a brief in support of an appeal 530 265 Plant filing fee 1403 290 2403 145 Request for oral hearing 2004 1004 770 385 Reissue filing fee 1005 160 2005 80 Provisional filing fee 1451 1,510 1451 1,510 Petition to institute a public use proceeding 1452 110 2452 55 Petition to revive - unavoidable SUBTOTAL (1) (\$) 385.00 1453 1,330 2453 665 Petition to revive - unintentional 2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE 1501 1,330 2501 665 Utility issue fee (or reissue) Fee from Extra Claims Fee Paid below 1502 480 2502 240 Design issue fee **Total Claims** -20** = 1 xl9 9.00 1503 640 2503 320 Plant issue fee Independent 1460 130 1460 130 Petitions to the Commissioner Multiple Dependent 1807 50 1807 50 Processing fee under 37 CFR 1.17(q) Large Entity Small Entity 1806 180 1806 180 Submission of Information Disclosure Stmt Fee Fee Fee Description Fee 40 Recording each patent assignment per Code (\$) Code (\$) 8021 40 8021 property (times number of properties) Claims in excess of 20 1202 18 2202 9 385 Filing a submission after final rejection (37 CFR 1.129(a)) 1809 770 2809 Independent claims in excess of 3 1201 86 2201 43 1203 290 Multiple dependent claim, if not paid 2203 145 1810 770 2810 385 For each additional invention to be examined (37 CFR 1.129(b)) 1204 86 2204 43 Reissue independent claims over original patent 1801 770 2801 385 Request for Continued Examination (RCE) ** Reissue claims in excess of 20 900 1802 900 Request for expedited examination 1205 18 2205 9 1802 and over original patent of a design application Other fee (specify) (\$) 394.00 SUBTOTAL (2) *Reduced by Basic Filing Fee Paid (\$) SUBTOTAL (3) **or number previously paid, if greater; For Reissues, see above SUBMITTED BY (Complete (if applicable)) Registration No. Name (Print/Type) Brian Lewis 32,502 Telephone (650) 384-8650 (Attorney/Agent) December 5, 2003 Signature Date

> WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.